Trading at less than cash and pipeline is worth more than $100 million anyway.I'm not sure about the Javelin gamble makes much sense, but at least it didn't use cash to get it.
What everyone else said
Valued below cash on hand. Jumping ahead of ZZLangerhans based on his excellent may 25 blog. Going long at $4.10 prox.
Very undevalued. Market value $130 million, cash $181 million. 3 drus in clic; 3 preclinic.
Lead drug candidate suspended...this is a cash play. Following the just recently announced termination of development of Azixa, there was the expected sell-off, but there wasn't a huge drop in price and it has recovered to pre-announcement levels, so it would appear that the market is being very mindful of their cash position. The remaining drugs in the pipeline aren't terribly advanced in development, and it will be interesting to see where the newly appointed CEO will take Myrexis from here.
Biotech trading for less than their cash
bought in real life at $4.50 and $4.70... definitely one of the top stocks in my real portfolio.
The are a buy out target
Taking my chances that one of their big boppers will be a winner
I just think that 100millUSD is too low a valuation for a pipeline of potentially blockbuster drugs. Yes, they could dilute their shares away and trade for 10c eventually, but that is a 100% downside vs. a 1,000% upside. I am fine with those odds because overall the biotech index trades upwards. I suspect that if you were to remove the post success biotechs from the index, the group would be doing even better. So invest pre-success and cast a wide net.
The pipeline looks nice, but... what do I know about these things? No debt, decent amount of cash on hand. For a speculative play on an emerging biotech, you just have to follow the trend sometimes. Looks like it's trending up, to me.
lots of cash
Company has no debt and 180millon dollars in the bank and a very intersting pipe line, that we should get some info by the end of year. The market cap is 110.20 millon and more cash than market value a no brainer
focus on Azixa trials
Technically oversold with a nice balance sheet. Recent insider buys don't hurt either.
For details about CAPS-UK, and the conditions you agree to be bound by, please see our
Terms and Conditions.
© Copyright 1998-2013, The Motley Fool Limited. All rights reserved. This material is for personal use only.
The Motley Fool, Fool, and the "Fool" logo are registered trademarks of The Motley Fool, Holdings, Inc.
Place of Reg: England & Wales. Company Reg No: 3736872. VAT Reg No: 945 6990 68. Registered Office: 5th Floor, 60 Charlotte Street London W1T 2NU.
This page brought to you by USEQ\WEB22.